Phase 2 N=36 First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Primary: Median Overall Survival — 13.9 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=310 A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
Bladder Cancer
Primary: Percentage of Participants With a Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed by the Independent Review Facility (IRF)…
Phase 3 N=931 A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
Bladder Cancer
Primary: Overall Survival (OS) — 10.6; 11.1; 8.2; 8.9 Months — p=0.4134
Phase 3 N=1,004 A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Urinary Tract Cancer
Primary: Percentage of Participants With Adverse Events (AEs) — 900 Participants
Phase 2 N=119 A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)
Bladder Cancer
Primary: Percentage of Participants With a Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed by the Independent Review Facility (IRF)…
Phase 3 N=1,213 Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Primary: Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm…
Phase 3 N=700 A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
Urothelial Cancer
Primary: Overall Survival (OS) — 21.4; 14.3 months — p=0.0005
Phase 2 N=49 Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Metastatic Urothelial Cancer
Primary: Objective Response Rate (ORR) — 69.6; 33.3 Percentage of participants
Phase 2 N=113 Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer
Locally Advanced or Metastatic Urothelial Bladder Cancer
Primary: Objective Response Rate (ORR) as Assessed by Independent Review Committee (IRC) — 24.0 Percentage of participants — p=< 0.0001
Phase 2 N=43 CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Bladder Cancer
Primary: Objective Response Rate (ORR) — 1; 2 Participants
Phase 2 N=20 Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 · Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 · Stage IV Bladder Urothelial Carcinoma AJCC v7
Primary: Progression-free Survival (PFS) — 11.4 months
Phase 2 N=23 Neoadjuvant Atezolizumab in Localized Bladder Cancer
Carcinoma, Transitional Cell
Primary: Mean log2 (Fold Change of CD3+ T-Cell Count/µm2) Over Time — -0.036; -0.041; 1.516 log2(fold change)
Phase 2 N=36 Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma · Bladder Cancer
Primary: Count of Participants With Response Measured by RECIST 1.1 — 16 Participants
Phase 2 N=78 Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer
Metastatic Urothelial Carcinoma
Primary: Number of Participants With Overall Response — 9; 8 Participants
Phase 2 N=69 Cabozantinib for Advanced Urothelial Cancer
Urothelial Carcinoma · Urethral Neoplasms · Urinary Bladder Neoplasms
Primary: Percentage of Participants With Overall Response — 19.1; NA; NA percentage of participants
Phase 2 N=36 Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer
Urothelial Carcinoma
Primary: Percentage of Patients That Respond to Treatment — 18 Participants
Phase 2 N=219 A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Carcinoma, Transitional Cell · Urinary Bladder Neoplasms · Urologic Neoplasms
Primary: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) — 44; 51.7 Percentage of Participants
Phase 3 N=542 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Urothelial Cancer
Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - All Participants — 3.3; 2.1 Months — p=0.41648
Phase 2 N=29 Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
Bladder Cancer
Primary: Percentage of Patients With Complete Pathologic Response After 3 Cycles of Treatment — 27.3 percentage of patients
Phase 2 N=13 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
Urothelial Carcinoma · Ureteral Neoplasms · Ureter Cancer
Primary: Progression Free Survival — 1.9 Months
Phase 3 N=506 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Advanced Urothelial Carcinoma · Metastatic Bladder Urothelial Carcinoma · Metastatic Prostate Carcinoma
Primary: Overall Survival (OS) — 14.5; 14.3 months — p=0.1707
Phase 2 N=47 Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
Advanced Bladder Urothelial Carcinoma · Advanced Ureter Urothelial Carcinoma · Metastatic Bladder Urothelial Carcinoma
Primary: Objective Response Rate (ORR) — 3; 4; 0; 2 Participants — p=0.428
Phase 2 N=32 Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
Invasive Bladder Cancer
Primary: Proportion of Patients With Pathological Response — 26; 2 Participants
Phase 3 N=84 Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
UC (Urothelial Cancer)
Primary: Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo — 21.4; 9.5 percentage of participants
Phase 2 N=26 Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
Urothelial Carcinoma
Primary: Objective Response Rate — 8.3 Percentage of participants
Phase 2 N=39 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter · Proximal Urethral Cancer
Primary: Objective Response Rate — 56.4 percentage of participants
Phase 2 N=43 BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
Muscle Invasive Bladder Cancer
Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…
Phase 2 N=60 Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer
Bladder Cancer
Primary: Percentage of Participants With Response Defined as the Absence of Residual Muscle Invasive Cancer in Resected Specimen — 38; 53 Percentage of Participants
Phase 2 N=28 Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
Bladder Cancer
Primary: The Number of Participants Experiencing an Unacceptable Level of Toxicity as Defined Below — 9; 6; 2; 4 Participants
Phase 2 N=83 Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Urothelial Carcinoma · Bladder Cancer
Primary: Phase Ib: Safety of Pembrolizumab in Combination With Gemcitabine-Cisplatin — 0 Participants